Market Overview

Rosetta Genomics Announces Agreement with MultiPlan for its PersonalizeDx Suite of Testing Services

Share:

osetta Genomics Announces Agreement with MultiPlan for its PersonalizeDx
Suite of Testing Services
Provides access to molecular assays for bladder, lung, prostate and breast
cancer for nearly 68 million Americans
PRINCETON, N.J. & REHOVOT, Israel--(BUSINESS WIRE)--June 16, 2015--
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of
microRNA-based molecular diagnostics, announces that PersonalizeDx, a
Rosetta Genomics company, has executed a network participation agreement
with MultiPlan, Inc. (MultiPlan) for the entire suite of PersonalizeDx
testing and services effective July 1, 2015.
MultiPlan provides healthcare cost management solutions, including preferred
provider networks (PPOs). More than 900,000 healthcare providers participate
in MultiPlan's networks, and the company reprices 40 million claims each
year. It is estimated that 68 million Americans have access to MultiPlan's
networks. In addition to offering regional PPO networks in Wisconsin and the
southwest, Multi-Plan offers the leading independent national primary PPO
and one of the largest complementary networks in the United States. As a
result of this agreement, PersonalizeDx is one of those participating
healthcare providers.
A PPO is a managed care organization of medical doctors, hospitals and other
health care providers that has covenanted with an insurer or a third party
administrator (TPA) to provide health care at reduced rates to the insurer's
or administrator's clients.
"Through our recent acquisition of PersonalizeDx, we now offer a broader
menu of molecular and other assays for bladder, lung, prostate and breast
cancer patients that enable personalized medicine and help improve patient
outcomes. This agreement enhances our ability to offer these valuable
testing services to MultiPlan's participating members, providers, payers and
TPAs," noted Kenneth A. Berlin, President and Chief Executive Officer of
Rosetta Genomics. "Importantly, this agreement is expected to significantly
enhance both the timing and percentage of payments for our testing services,
which is a key factor in achieving efficiency in the delivery and
distribution of our differentiated content. We look forward to working with
the MultiPlan team and to executing additional agreements such as this that
broaden access to our growing portfolio of molecular diagnostics and testing
services."

 

Related Articles (ROSG)

View Comments and Join the Discussion!

Posted-In: M&A News Press Releases

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com